Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics

This study has been completed.
Sponsor:
Collaborator:
INC Research Limited
Information provided by (Responsible Party):
Savara Inc.
ClinicalTrials.gov Identifier:
NCT01537666
First received: February 17, 2012
Last updated: March 3, 2014
Last verified: March 2014

February 17, 2012
March 3, 2014
November 2011
March 2012   (final data collection date for primary outcome measure)
Safety and Tolerability - Number of Participants With Treatment Emergent Adverse Events (TEAEs = Adverse Events That Started During or After the First Dose of Study Drug) [ Time Frame: Healthy volunteers = 2 weeks; CF Patients = 1 week ] [ Designated as safety issue: Yes ]
Each participant was monitored regularly for Adverse Events (AEs) throughout the study. The Investigator or designee enquired about AEs by asking participants non-leading questions such as: "How do you feel?" or "Have you had any (other) medical problems since your last visit/assessment?" Additionally, several safety procedures (physical examinations, vital signs, safety laboratory tests, 12-lead ECGs, and spirometry) were conducted on participants at regular intervals. All AEs reported spontaneously by participants or in response to questioning or observation by the Investigator, including those related to safety procedures, were recorded. For each AE, the Investigator recorded the following assessments: seriousness, severity (Mild, Moderate, or Severe), and relationship to study drug (Not Related, Remote, Possible, Probable, or Highly Probable). AEs were considered drug-related if given a relationship of Possible, Probable, or Highly Probable.
Tolerability and safety [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]
Local tolerability and safety of the AeroVanc powder is measured by recording adverse events and measurement of pulmonary function.
Complete list of historical versions of study NCT01537666 on ClinicalTrials.gov Archive Site
  • Plasma Pharmacokinetics - Elimination Half Life (t½) [ Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose ] [ Designated as safety issue: No ]

    Blood samples were obtained from the healthy volunteers to evaluate systemic pharmacokinetics of vancomycin after a single dose administration of AeroVanc or a single dose of IV vancomycin.

    Half-life is the time it takes for the concentration of drug to decline by 50%.

  • Plasma Pharmacokinetics - Time to Reach the Maximum Plasma Concentration (Tmax) [ Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose ] [ Designated as safety issue: No ]

    Blood samples were obtained from the healthy volunteers to evaluate systemic pharmacokinetics of vancomycin after a single dose administration of AeroVanc or a single dose of IV vancomycin.

    Tmax is the time it takes to reach the maximum plasma concentration of a drug.

  • Plasma Pharmacokinetics - Maximum Plasma Concentration (Cmax) [ Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose ] [ Designated as safety issue: No ]

    Blood samples were obtained from the healthy volunteers to evaluate systemic pharmacokinetics of vancomycin after a single dose administration of AeroVanc or a single dose of IV vancomycin.

    Cmax is the maximum observed concentration of a drug.

  • Plasma Pharmacokinetics - Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUCt) [ Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose ] [ Designated as safety issue: No ]

    Blood samples were obtained from the healthy volunteers to evaluate systemic pharmacokinetics of vancomycin after a single dose administration of AeroVanc or a single dose of IV vancomycin.

    AUCt is a way of expressing the total amount of drug exposure over a specified time period.

  • Plasma Pharmacokinetics - Area Under the Plasma Concentration-time Curve From Time 0 to Infinite Time (AUCinf) [ Time Frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose ] [ Designated as safety issue: No ]

    Blood samples were obtained from the healthy volunteers to evaluate systemic pharmacokinetics of vancomycin after a single dose administration of AeroVanc or a single dose of IV vancomycin.

    AUCinf is a way of estimating the total amount of drug exposure over an infinite time period.

  • Lung Pharmacokinetics - Maximum Sputum Concentration (Cmax) [ Time Frame: 1, 8 and 24 hours post-dose ] [ Designated as safety issue: No ]

    Sputum samples were obtained from the patients with cystic fibrosis to evaluate lung pharmacokinetics of vancomycin after a single dose administration of AeroVanc.

    Cmax is the maximum observed concentration of a drug.

  • Lung Pharmacokinetics - Minimum Sputum Concentration (Cmin) [ Time Frame: 1, 8 and 24 hours post-dose ] [ Designated as safety issue: No ]

    Sputum samples were obtained from the patients with cystic fibrosis to evaluate lung pharmacokinetics of vancomycin after a single dose administration of AeroVanc.

    Cmin is the minimum observed concentration of a drug.

  • Systemic pharmacokinetics [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
    Blood samples are obtained from the healthy volunteers to evaluate systemic pharmacokinetics of vancomycin after a single dose administration of aeroVanc.
  • Lung pharmacokinetics [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
    Sputum samples are obtained from the patients with cystic fibrosis to evaluate lung pharmacokinetcs of vancomycin after a single dose administration of AeroVanc.
Not Provided
Not Provided
 
Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics
Phase I, Reference-controlled, Dose Escalating Study to Examine the Pharmacokinetics and Safety of AeroVanc Inhalation Powder.

The study is carried out to evaluate the safety, tolerability and pharmacokinetics of AeroVanc inhalation powder in healthy volunteers, and in patients with cystic fibrosis.

The study has three main objectives:

  • To evaluate the safety, and tolerability of AeroVanc inhalation powder in healthy volunteers, and in patients with CF.
  • To determine the systemic bioavailability of vancomycin in healthy volunteers following single dose pulmonary administration of 16 mg, 32 mg, and 80 mg doses of AeroVanc in comparison with a 250 mg dose of vancomycin administered intravenously.
  • To estimate the lung sputum concentrations of vancomycin in patients with cystic fibrosis (CF) following single dose pulmonary administration of 32 mg and 80 mg doses of AeroVanc.
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Healthy
  • Cystic Fibrosis
  • Drug: AeroVanc
    Vancomycin hydrochloride dry powder for inhalation
  • Drug: IV vancomycin hydrochloride
    Vancomycin hydrochloride solution for intravenous administration
  • Experimental: Aerovanc 16 mg in healthy volunteers
    Intervention: Drug: AeroVanc
  • Experimental: AeroVanc 32 mg in healthy volunteers
    Intervention: Drug: AeroVanc
  • Experimental: AeroVanc 80 mg in healthy volunteers
    Intervention: Drug: AeroVanc
  • Active Comparator: IV vancomycin in healthy volunteers
    Intervention: Drug: IV vancomycin hydrochloride
  • Experimental: AeroVanc 32 mg in CF patients
    Intervention: Drug: AeroVanc
  • Experimental: AeroVanc 80 mg in CF patients
    Intervention: Drug: AeroVanc
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
March 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria Healthy Volunteers:

  1. Healthy male volunteers between 18 and 50 years of age inclusive.
  2. Able to communicate with site personnel and to understand and voluntarily sign the Informed Consent Form.
  3. Able and willing to comply with the Protocol, including availability for all scheduled study visits.
  4. Body Mass Index (BMI) of 20 to 30 kg/m2 inclusive, and weight between 60-90 kg inclusive.
  5. No clinically significant abnormalities at screening determined by medical history, physical examination, blood chemistry, hematology, urinalysis, and 12-lead ECG. Negative urine screen for drugs of abuse and negative alcohol breath test at Screening and prior to dosing.
  6. Negative human immunodeficiency virus (HIV) and Hepatitis B and Hepatitis C screening test results.
  7. Spirometry (forced expiratory volume in 1 second (FEV1)) value at screening greater than 75% of predicted age-adjusted value.

Exclusion Criteria Healthy Volunteers:

  1. A history of pulmonary or other disorder likely to influence drug absorption.
  2. Evidence or suspicion of clinically significant respiratory, renal, hepatic, central nervous system, cardiovascular or metabolic dysfunction.
  3. A history of previous allergies or sensitivity to vancomycin, or other component(s) of the study drug or reference drug.
  4. Smokers (ex-smokers who quit smoking must have a one year period of not smoking prior to the study drug administration).
  5. Respiratory tract infection within the last two weeks prior to the first study drug administration.
  6. Treatment with any prescription medication and/or over-the-counter (OTC) products including vitamins or mineral supplements within 48 hours before Investigational Product administration.
  7. Vaccination within one month before the study drug administration.
  8. Systolic blood pressure <110 mmHg or >150 mmHg inclusive or diastolic blood pressure <60 mmHg or >90 mmHg inclusive.
  9. A history of drug or alcohol abuse.
  10. Participation in a clinical study within three months on Investigational Product administration.
  11. Donation of blood or plasma within three months of Investigational Product administration.
  12. Any other condition which in the view of the Investigator is likely to interfere with the study or put the subject at risk.

Inclusion Criteria CF Patients:

  1. Able to communicate with site personnel and to understand and voluntarily sign the Informed Consent Form.
  2. Able and willing to comply with the protocol, including availability for all scheduled study visits.
  3. Have a confirmed diagnosis of cystic fibrosis (by two established methods, e.g. positive sweat chloride value ≥ 60 mEq/L, nasal potential difference test, and/or genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with the CF phenotype).
  4. Be aged ≥ 18 years old
  5. Have FEV1 >40 % of predicted
  6. Be able to perform all the techniques necessary to measure lung function
  7. No liver enzymes increased by more than twice the upper limit of normal
  8. Ability to spontaneously produce bronchial sputum daily

Inclusion Criteria CF Patients:

  1. Administration of any investigational drug or device within 28 days of Screening and within six half-lives of the investigational drug.
  2. Oral corticosteroids in doses exceeding 10 mg per day or 16 mg every other day.
  3. History of sputum culture or throat swab culture yielding B. cepacia in the previous two years.
  4. History of positive MRSA culture, or sputum culture positive for MRSA at screening.
  5. Current daily continuous oxygen supplementation or requirement for more than 2 L/min at night.
  6. A history of previous allergies or sensitivity to vancomycin, or other component(s) of the study drug.
  7. Changes in antimicrobial, bronchodilator, anti-inflammatory or corticosteroid medications within 7 days prior to Screening.
  8. Changes in physiotherapy technique or schedule within 7 days prior to Screening.
  9. History of lung transplantation.
  10. A chest X-Ray at Screening or within the previous 90 days of Screening, with abnormalities indicating a significant acute finding (e.g., lobar infiltrate and atelectasis, pneumothorax, or pleural effusion).
  11. Positive pregnancy test. All women of childbearing potential will be tested.
  12. Female of childbearing potential who is lactating or is not practicing acceptable method of birth control (e.g., hormonal or barrier methods, or intrauterine device).
  13. Findings at Screening that, in the investigator's opinion, would compromise the safety of the subject or the quality of the study data.
  14. History of severe cough/bronchospasm upon inhalation of dry powder inhalation product.
  15. Considered "terminally ill" or eligible for lung transplantation.
  16. Have had a significant episode of hemoptysis (>60 mL) in the three months prior to enrolment.
Both
18 Years to 50 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Australia
 
NCT01537666
SAV005-01
Yes
Savara Inc.
Savara Inc.
INC Research Limited
Not Provided
Savara Inc.
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP